ABL Bio Inc. (KOSDAQ:298380)

South Korea flag South Korea · Delayed Price · Currency is KRW
70,100
-2,000 (-2.77%)
Jul 16, 2025, 3:30 PM KST
146.40%
Market Cap3.40T
Revenue (ttm)27.63B
Net Income (ttm)-71.71B
Shares Out48.53M
EPS (ttm)-1,489.50
PE Ration/a
Forward PE117.26
Dividendn/a
Ex-Dividend Daten/a
Volume832,292
Average Volume809,323
Open70,300
Previous Close72,100
Day's Range67,900 - 70,600
52-Week Range24,050 - 84,000
Beta0.72
RSI51.90
Earnings DateAug 11, 2025

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
CEO Sang Hoon Lee
Employees 102
Stock Exchange KOSDAQ
Ticker Symbol 298380
Full Company Profile

Financial Performance

In 2024, ABL Bio's revenue was 33.40 billion, a decrease of -49.04% compared to the previous year's 65.55 billion. Losses were -55.53 billion, 1998.1% more than in 2023.

Financial Statements

News

There is no news available yet.